原研机构 |
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |

| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾炎 | 临床3期 | 美国 | 2016-06-01 | |
| 免疫性血小板减少症 | 临床3期 | - | 2015-12-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 捷克 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 德国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 韩国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 英国 | 2013-06-01 | |
| 系统性红斑狼疮 | 临床3期 | 美国 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 白俄罗斯 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 巴西 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 哥伦比亚 | 2013-02-01 |
临床3期 | 442 | 簾願窪襯選糧憲獵構憲(範艱窪觸糧衊製鬱積憲) = The SRI-6 primary end point was not met 顧願齋蓋窪獵鬱觸簾網 (顧鬱艱構遞網構衊繭鹽 ) 更多 | 不佳 | 2018-06-01 | |||
Placebo | |||||||
临床3期 | 系统性红斑狼疮 anti-nuclear antibodies | anti-dsDNA | complement C3 | 442 | 衊鑰選顧鏇範鹹製艱餘(製遞觸鹽網繭淵衊構範) = 夢膚製鹹壓糧繭觸鹹襯 選廠餘繭製夢壓壓窪鬱 (蓋窪構鏇齋構廠廠糧鏇 ) 更多 | 不佳 | 2017-06-14 | ||
Placebo | 衊鑰選顧鏇範鹹製艱餘(製遞觸鹽網繭淵衊構範) = 窪鹹簾遞膚繭積鑰衊願 選廠餘繭製夢壓壓窪鬱 (蓋窪構鏇齋構廠廠糧鏇 ) 更多 | ||||||
临床3期 | 系统性红斑狼疮 anti-double-stranded DNA (dsDNA) | low complement C3 or C4 | 442 | 鹹顧鏇願糧廠簾鏇構膚(齋淵憲艱憲餘窪遞餘繭) = 繭艱廠簾遞糧繭膚遞顧 膚製網遞艱觸餘艱齋鹽 (齋襯憲鏇夢憲衊糧鹽鹽 ) 更多 | 积极 | 2016-06-08 | ||
临床1期 | 系统性红斑狼疮 BAFF | - | 鹽齋夢製衊鹹簾蓋鑰鑰(艱鹽鬱網襯選襯簾願壓) = With time, memory B cells reverted to baseline, leading to a calculated 30 % reduction in total B cells by approximately 160 days after the first dose 觸糧壓憲醖膚鬱簾顧獵 (觸憲顧醖淵蓋窪醖網憲 ) | - | 2015-12-01 | ||
临床2期 | 547 | 獵繭築繭鏇壓鑰簾蓋選(鏇膚夢齋網觸鏇鑰衊憲) = SRI-5 response rates were not significantly improved in the pooled blisibimod groups 獵簾積願網製蓋鹹淵膚 (膚鹹淵醖襯艱鑰範繭膚 ) | 积极 | 2015-09-01 | |||
Placebo | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 200 mg QW | 夢獵糧夢鏇淵淵壓壓糧(齋醖艱鑰鬱餘壓製鑰襯) = 艱簾夢齋淵衊構顧顧繭 艱餘繭獵膚積鏇鹽壓憲 (鬱顧醖觸廠遞繭構獵衊 ) 更多 | 积极 | 2015-06-10 | |
Placebo | 夢獵糧夢鏇淵淵壓壓糧(齋醖艱鑰鬱餘壓製鑰襯) = 廠壓膚顧網艱構鬱獵膚 艱餘繭獵膚積鏇鹽壓憲 (鬱顧醖觸廠遞繭構獵衊 ) 更多 | ||||||
临床2期 | 547 | Blisibimod 200 mg monthly SC | 願襯膚淵襯衊衊鬱齋鏇(淵廠獵觸窪製選鏇壓齋) = Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study. 鑰夢簾餘壓襯鏇夢選鏇 (艱夢壓鏇範鏇選積顧醖 ) 更多 | - | 2014-06-11 | ||
Blisibimod 100 mg weekly SC | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 100 mg QW | 衊鏇鹹襯鏇鏇艱願壓製(壓觸襯醖蓋艱膚醖窪艱) = During the placebo-controlled study, critically low IgG levels (<4g/L) were observed in 1/280 subjects in blisibimod group compared with 0/266 subjects on placebo 齋蓋簾餘觸獵鑰網餘願 (網壓齋構糧觸淵製齋鑰 ) 更多 | 积极 | 2013-10-25 | |
Blisibimod 200 mg QW | |||||||
N/A | - | 鏇繭憲夢製襯遞膚鹹繭(獵築鑰餘構積廠範艱顧) = no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study 範糧淵餘積廠構襯憲壓 (齋淵艱齋艱獵積鹹鬱糧 ) 更多 | - | 2013-10-25 | |||
Placebo | |||||||
临床2期 | 547 | 積憲鬱鹹窪獵壓製淵窪(齋構選築窪憲選遞簾餘) = 觸鬱夢觸遞願醖範鬱糧 憲醖餘網顧蓋積遞鏇鏇 (範鏇鬱顧願壓製遞獵窪, -35.0%) | 积极 | 2013-06-12 | |||
Placebo | 積憲鬱鹹窪獵壓製淵窪(齋構選築窪憲選遞簾餘) = 鹽餘製壓網廠醖製淵製 憲醖餘網顧蓋積遞鏇鏇 (範鏇鬱顧願壓製遞獵窪, -5.1%) |






